TYRA · Tyra Biosciences, Inc.

Track TYRA — free

$20.39 +0.15 (+0.74%) At close · Oct 7

Russell 2000 member Rebalance outlook locked

Market Cap

$1.22B

59.68M

Volume · Oct 7 477.74K Avg daily vol (3M) 853.48K

Up next

Next earnings call

Feb 10, 2027 Est · unconfirmed · in 18 wks

Latest filing: 10-Q

filed Aug 4, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

—

Trailing 12 months

Net income (TTM)

−$148.56M

Trailing 12 months

Revenue growth YoY

—

Year over year

Operating margin

—

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

-8.5%

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

$73.83M

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+10.8%

Year over year · more shares

Price change (1Y)

+50.7%

Trailing year

Short interest

16.6%

Latest settlement · 5.7 days to cover

View all 115 metrics

Equibles Rating

blended score · not investment advice

Overall

Strong Sell

SellHoldBuy

Technical Sell Momentum Very Weak Sentiment Neutral Fundamentals Poor Quant / Vol Very High

Market backdrop VIX 15.1 · calm Equity put/call 0.63

Technical

price trend

Sell

50 / 200-day cross No cross

Price vs 200-day avg −33%

below

Price vs 50-day avg −19%

below

RSI (14) 36

neutral

MACD trend Negative

52-week position 27%

mid-range

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Very Weak

1-month return −7%

trailing

6-month return −42%

trailing

YTD return −22%

this year

Relative strength −53%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $25 › 200d $30 — 200d above 50d

Institutional flow Flat

1 of 170 funds reported for Sep 30 · net 0 sh shares

Insider flow Accumulating

Net +$20.0K over 90 days · 0% sells

Short interest Rising

16.55% of float · ▲ +4.6% MoM · 5.7 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

170 holders — near 3-yr high, broad support

Squeeze score 67

elevated · 0–100

Fundamentals

Poor

EPS growth −33%

Y/Y

Free cash flow $-95.3M

Quant / Vol

risk profile

Very High

Volatility 68%

annualized · 1-yr

Max drawdown −49%

past year

ATR 7.7%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell

3 · 4 · 0

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

−33% Bearish

Price vs 50-day avg

−19% Bearish

RSI (14)

36 Neutral

MACD trend

Negative Bearish

52-week position

27% Neutral

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bullish · 2 of 6

Trend (MA cross) No cross

50d $25 › 200d $30 — 200d above 50d

Institutional flow Flat

1 of 170 funds reported for Sep 30 · net 0 sh shares

Insider flow Accumulating

Net +$20.0K over 90 days · 0% sells

Short interest Rising

16.55% of float · ▲ +4.6% MoM · 5.7 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

170 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $13 Now $20 · 27% Range high $40

vs 200-day avg -33% vs 50-day avg -19%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
TYRA Tyra Biosciences, Inc. this stock	$1.22B	-22.4%	—	—	16.6%
VRTX Vertex Pharmaceuticals Inc / Ma	$128.16B	+11.5%	+46.2%	29.5	1.9%
MRNA Moderna, Inc.	$78.44B	+566.3%	+4.3%	—	8.2%
REGN Regeneron Pharmaceuticals, Inc.	$76.40B	-3.9%	+20.8%	18.4	2.5%
CSLLY Csl Ltd	$61.25B	—	—	—	0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders

Holders

170

% held: 117.0%
Reported: 1 of 170
Top holder: RA CAPITAL MANAGEMENT, L.…

Held Float

View

Held by Funds

Fund positions

201

View

Short & Settlement

Short Interest Rising

Shares short

9.9M

Days to cover: 5.7d
Change: +436.7K sh

View

Short Volume

Short vol %

82%

As of: Oct 7, 2026

Short Total

View

Fails to Deliver

FTD shares

9.0K

Value: $197.3K
As of: Sep 14, 2026

View

Off-Exchange

Off-exchange %

41.0%

Week of: Aug 31, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net buying

Net (90d)

+$20.0K

Buyers / Sellers: 1 / 0

Buyers Sellers

View

Financials

Net income (FY)

$-119.9M

EPS diluted: $-2.01

View

Filings

SEC Filings

Latest

8-K

Filed: Sep 15, 2026
This year: 14

View

Proposed Sales

Value

$2.0M

Shares: 53.2K
Filed: Mar 26, 2026

View

Exempt Offerings

Offering

$200.0M

Filed: Feb 13, 2024

View

Earnings & Events

Webcasts

Last webcast

Sep 9, 2026

View

Performance

	5D	20D	120D	MTD	YTD
TYRA	-6.8%	-7.4%	-41.9%	-6.8%	-22.4%
SPY	+1.9%	+1.9%	+10.8%	+1.9%	+14.0%
vs SPY	-8.7%	-9.3%	-52.7%	-8.7%	-36.4%

Key facts CIK 1863127 CUSIP 90240B106 13F (30d) 3 filings 3 filers Visit website Investor relations

TYRA · Tyra Biosciences, Inc.

Price & Indicators

Up next

Metrics snapshot

Equibles Rating

Technicals

Key metrics

Versus peers

At a glance

Performance